Figure 5.

Pharmacological specificity of cannabinoid agonist-induced suppression of paclitaxel-induced mechanical and cold allodynia. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated suppression of paclitaxel-induced mechanical allodynia was dominated by CB1 receptor activation with some involvement of CB2 receptors. b. The AM1710 (3.2 mg/kg/day s.c.)-induced suppression of paclitaxel-induced mechanical allodynia was blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). c. Neither AM630 (3 mg/kg/day s.c.) nor AM251 (3 mg/kg/day s.c.) reliably altered the anti-allodynic effects of WIN55,212-2 (0.5 mg/kg/day s.c.) following acetone application. d. AM630 (3 mg/kg/day s.c.), but not AM251 (3 mg/kg/day s.c.), blocked the anti-allodynic effects of AM1710 (3.2 mg/kg/day s.c.) to cold stimulation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Taxol-Vehicle, ++P < 0.01 vs. Taxol-Agonist, xxP < 0.01, xxxP < 0.001 Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, tP < 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM630 (3), and Cremophor-Vehicle, ϕP < 0.05, ϕϕP < 0.01, ϕϕϕP < 0.001 Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Taxol-Agonist, P < 0.05, ⟂⟂P < 0.01, ⟂⟂⟂P < 0.001 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3), and Cremophor-Vehicle, δP < 0.05, δδδP <0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Taxol-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27
Download authors' original image